VGX-3100: Phase I data

Data from an open-label, dose-escalation, U.S. Phase I trial showed that 13 of 18 women with a previous history of cervical intraepithelial neoplasia (CIN) 2/3 treated with 0.6, 2 or 6 mg intramuscular VGX-3100 delivered by Inovio's CELLECTRA electroporation system developed significant antigen-specific cytotoxic T lymphocyte (CTL) responses, with positive responses ranging from <100 to >5,000 spot forming units (SFU) per million cells. Additionally, 15 vaccinated patients developed antibody responses to >=1 antigen component tested. ...